EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)

Chenru Zhao, Daoran Lu, Jianjun Gao

Drug Discoveries & Therapeutics · 31.08.2025 · 19 (4) · 275-276

DOI: 10.5582/ddt.2025.01058 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Discoveries & Therapeutics, erschienen am 31.08.2025. Verfasst von Chenru Zhao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-met, Immunoconjugates. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Telisotuzumab vedotin represents a clinically important antibody-drug conjugate (ADC) that received accelerated approval from the US Food and Drug Administration in May 2025, establishing it as the first-in-class targeted therapy for adult patients with immunohistochemistry (IHC)-confirmed high-c-Met, EGFR wild-type, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Its mechanism of action relies on precise targeting of the c-Met protein receptor, followed by internalization and release of the potent cytotoxic payload monomethyl auristatin E (MMAE) to eradicate tumor cells. The pivotal phase II LUMINOSITY trial demonstrated that the high c-Met overexpressing group had an overall response rate (ORR) of 34.6%. This therapeutic agent addresses a critical unmet need within a molecularly defined NSCLC subpopulation, marking a substantial advancement in c-Met-targeted oncology. The regulatory authorization and clinical use of telisotuzumab vedotin may significantly advance precision medicine for NSCLC, though an ongoing phase III trial will further confirm its efficacy and safety and determine its eligibility for full regulatory approval in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-metImmunoconjugatesHumansUnited StatesDrug ApprovalUnited States Food and Drug Administration

Stichwörter der Autor:innen

METNSCLCTeliso-Vlung cancer

Substanzen

Proto-Oncogene Proteins c-metImmunoconjugatesMET protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China.
  • Department of Pharmacology, School of Pharmacy, Qingdao Medical College, Qingdao University, Qingdao, Shandong, China.

Zitieren

APA

Zhao, C., Lu, D., & Gao, J. (2025). Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC). Drug Discoveries & Therapeutics, 19(4), 275-276. https://doi.org/10.5582/ddt.2025.01058

Vancouver

Zhao C, Lu D, Gao J. Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC). Drug Discoveries & Therapeutics. 2025;19(4):275-276. doi:10.5582/ddt.2025.01058

BibTeX
@article{Zhao2025,
  author = {Zhao, Chenru and Lu, Daoran and Gao, Jianjun},
  title = {Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)},
  journal = {Drug Discoveries & Therapeutics},
  year = {2025},
  volume = {19},
  number = {4},
  pages = {275--276},
  doi = {10.5582/ddt.2025.01058}
}
Kostenlos starten →